Candida glabrata Empyema Thoracis-A Post-COVID-19 Complication

Neeraja Swaminathan1, Katherine Anderson2, Joshua D Nosanchuk1

  • 1Department of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10467, USA.

Insights

COVID-19 survivors face increased fungal infections. This case highlights Candida glabrata fungal empyema thoracis, a rare complication requiring prompt diagnosis and specific antifungal strategies.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Mycology

Background:

  • The COVID-19 pandemic has seen a rise in invasive fungal infections.
  • Fungal empyema thoracis (FET) is a rare but serious complication of invasive fungal disease (IFD).
  • Effective management of non-bloodstream Candida infections remains challenging.

Observation:

  • A patient with post-COVID-19 pneumonia developed a polymicrobial empyema.
  • Candida glabrata was identified as a causative agent in the empyema.
  • This represents a novel manifestation of COVID-19-associated opportunistic fungal infection.

Findings:

  • Candida empyemas are an emerging complication of COVID-19.
  • This case underscores the need for high clinical suspicion for fungal infections in post-COVID-19 patients.
  • The first reported instance of Candida glabrata empyema thoracis post-COVID-19.

Implications:

  • Early detection and management of Candida empyema are crucial for improving patient outcomes.
  • Antifungal therapy for empyemas may need to differ from bloodstream infections due to pharmacokinetic challenges.
  • Further research is needed to optimize treatment for non-bloodstream Candida infections in the pleural space.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
392
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
437
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
305
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
253
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
1.4K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K